当前位置: 首页 >> 检索结果
共有 39712 条符合本次的查询结果, 用时 4.6792631 秒

121. Mechanistic Insights and Perspectives on AVL9-Mediated Chemoresistance in Pancreatic Ductal Adenocarcinoma.

作者: Xinyi Tang.;Jiaruo Xu.;Qingzhi Ran.;Yongkang Zhang.
来源: Gastroenterology. 2025年

122. The current status and prospects of gut microbiota combined with PD-1/PD-L1 inhibitors in the treatment of colorectal cancer: a review.

作者: Min Deng.;Xiaoyu Li.;Huiming Wu.;Dingwen Xue.;Yize Wang.;Renkai Guo.;Yipeng Cui.;Chenfei Jin.;Fei Luo.;Huiyu Li.
来源: BMC Gastroenterol. 2025年25卷1期380页
Colorectal cancer (CRC) is a common malignant tumor. Immune checkpoint inhibitors (ICIs), particularly those targeting programmed cell death protein 1(PD-1) and programmed cell death ligand 1(PD-L1), have shown promising potential in the treatment of CRC. Specific gut microbiota can modulate the efficacy of ICIs through immune or metabolic pathways. This review summarizes recent advances in the combined application of gut microbiota and PD-1/PD-L1 inhibitors in the treatment of CRC, aiming to provide insights for expanding clinical treatment options for CRC.

123. Fatigue, weakness, shoulder pains after achieving remission for 8 years - a rare case with an even more unusual presentation.

作者: Xuan-Qiu He.;Zhen Yang.;Guo-Xin Hu.
来源: Gastroenterology. 2025年

124. Comments on "Hypoxic and Acidic Tumor Microenvironment-Driven AVL9 Promotes Chemoresistance of Pancreatic Ductal Adenocarcinoma via the AVL9-IκBα-SKP1 Complex".

作者: Saisai Jing.;Jiazhao Song.
来源: Gastroenterology. 2025年

125. Enhanced Analytical Framework for Complex Biological Data: Beyond Principal Component Analysis in Cancer Research.

作者: Yoshiyasu Takefuji.
来源: Gastroenterology. 2025年

126. The Patient Prescription for Integrating Artificial Intelligence Into Gastroenterology Care.

作者: Kate Mason.;Megan Marsiglio.;Sam Jactel.
来源: Gastroenterology. 2025年

127. Associations of Alcohol Consumption and Genetic Predisposition to Hepatic Steatosis With Liver-Related Events: Results From Large Population-Based Cohort Studies.

作者: Hongliang Xue.;Liqing Wang.;Dianjianyi Sun.;Yuankai Wu.;Canqing Yu.;Yating Huang.;Sun On Chan.;Wenhua Ling.;Jun Lv.;Liming Li.;Xu Chen.;Yuanjie Pang.;Chao Yu.
来源: Gastroenterology. 2025年
The new classification for steatotic liver disease identifies 3 phenotypes based on alcohol consumption. The aim of this study was to evaluate the associations between alcohol intake and liver-related events (LREs) across different drinking categories and whether genetic predisposition influences these associations.

128. Reply.

作者: Jinsheng Ding.;Tianxing Zhou.;Jihui Hao.
来源: Gastroenterology. 2025年

129. A Rare Treatable Cause of Dysphagia and Odynophagia in a Lung Transplant Recipient.

作者: Abdillahi Ahmed.;Lehar Khanna.;Anil Sharma.
来源: Gastroenterology. 2025年

130. Revisiting Helicobacter pylori Eradication: Evolving Evidence and Global Implications for Gastric Cancer Prevention.

作者: Zong-Chao Liu.;Wen-Qing Li.
来源: Gastroenterology. 2025年

131. Role of liver transient elastography in detecting cirrhosis with esophageal and gastric varices and evaluating variceal severity.

作者: Chaozhi Wang.
来源: BMC Gastroenterol. 2025年25卷1期379页
To explore the application and clinical value of liver transient elastography (TE) in diagnosing and assessing the degree of liver cirrhosis combined with esophageal and gastric varices (EGV).

132. A systematic review of the epidemiology and risk factors for severity and recurrence of hypertriglyceridemia-induced acute pancreatitis.

作者: Jiongdi Lu.;Zhe Wang.;Wentong Mei.;Kaixin Peng.;Liang Zhang.;Gang Wang.;Kedong Xu.;Zheng Wang.;Yunpeng Peng.;Zipeng Lu.;Xiaolei Shi.;Guotao Lu.;Li Wen.;Feng Cao.; .
来源: BMC Gastroenterol. 2025年25卷1期374页
This systematic review aims to comprehensively assess the epidemiology and identify risk factors associated with the severity and recurrence of hypertriglyceridemia-induced acute pancreatitis (HTG-AP). A search of PubMed, Web of Science, and Cochrane databases was conducted to identify all relevant randomized controlled trials (RCTs), prospective, or retrospective cohort studies on HTG-AP. Data related to epidemiology and risk factors for severity and recurrence of HTG-AP were extracted and analyzed. Seventy-seven studies met the inclusion criteria, comprising 1 RCT, 21 prospective studies, and 55 retrospective studies. A total of 56,617 acute pancreatitis (AP) patients were included, of which 19.99% were diagnosed with HTG-AP (n = 11,315). Compared to non-HTG-AP patients, HTG-AP patients were more likely to be male (68.7% vs. 57.3%) and younger (mean age 41.47 ± 4.32 vs. 50.25 ± 7.70 years). HTG-AP patients exhibited higher mortality rates (up to 20% vs. 15.2%), increased severity (8.3% to 100% vs. 3.8% to 47.2%), and higher recurrence rates (up to 64.8% vs. 23.3%). Analysis of temporal trends from 2002 to 2023 showed a range of HTG-AP prevalence in overall AP patients from 1.6% to 47.6%, with a slight upward trend that was not statistically significant (P = 0.1081). Regional analysis indicated relatively stable prevalence in North America (P = 0.5787), Europe (P = 0.0881), other regions (P = 0.738), while prevalence in China showed a significant increase (P = 0.0119). Thirteen studies investigated risk factors affecting HTG-AP severity, with elevated serum triglyceride (TG) levels associated with increased risk of complications such as pancreatic necrosis, systemic inflammatory response syndrome (SIRS), shock, and multi-organ failure. Additional factors including high neutrophil-to-lymphocyte ratio (NLR), elevated levels of amylase and C-reactive protein (CRP), hypocalcemia, and hypoalbuminemia were also implicated in HTG-AP severity. Smoking history, poor lipid control (TG > 3.1 mmol/L), or recurrent hypertriglyceridemia during follow-up were identified as potential predictors of HTG-AP recurrence. Our findings indicate a stable global prevalence of HTG-AP within AP patients, but a notable increase in China, possibly attributed to socio-economic and dietary factors.

133. Clinical challenges and patient experiences in early-onset colorectal cancer: insights from seven European countries.

作者: Marianna Vitaloni.;Katell Maguet.;Andi Carlan.;Patricia Stack.;Vincent de Jong.;Ross Williams.;Zorana Maravic.
来源: BMC Gastroenterol. 2025年25卷1期378页
The incidence of early-onset colorectal cancer (eoCRC), defined as CRC diagnosed in individuals under 50, is rising globally. Younger patients often face diagnostic delays and receive care pathways designed for older populations. These gaps highlight the need for tailored approaches to diagnosis, treatment, and support.

134. Clinical outcomes of endoscopic retrograde cholangiopancreatography after Billroth II anastomosis: a comparison of gastroscope and duodenoscope.

作者: Kang Ho Lee.;Gwang Hyo Yim.;Jimin Han.;Han Taek Jeong.
来源: BMC Gastroenterol. 2025年25卷1期373页
Endoscopic retrograde cholangiopancreatography (ERCP) in patients with Billroth II anastomosis is challenging due to post-surgical anatomical alterations. This study aims to compare the clinical outcomes of using a duodenoscope and a cap-assisted gastroscope in these patients.

135. Changes in microbial and metabolic profiles of mice fed with long-term high salt diet.

作者: Huiying Tian.;Xiaotang Gao.;Hanlin Du.;Zhuofeng Lin.;Xianen Huang.
来源: BMC Gastroenterol. 2025年25卷1期375页
High salt diet (HSD) has been considered as a risk factor for the development of metabolic disorders. However, less is known about long-term implications of HSD. Therefore, the aim of this study was to conduct a preliminary investigation into the effects of mice feeding with long-term HSD on gut microbial and metabolic profiles.

136. Intravenous sedation during esophagogastroduodenoscopy is associated with a reduced risk of missed gastric cancer.

作者: Isabel Salvador.;Beatriz Arau.;Xavier Andújar.;Carme Ferrer.;Yamile Zabana.;Laura Ruiz.;Montserrat Aceituno.;Fernando Fernández-Bañares.;Maria Esteve.;Carme Loras.
来源: BMC Gastroenterol. 2025年25卷1期377页
Esophagogastroduodenoscopy (EGD) is an effective technique for diagnosing gastric cancer (GC). However, it is estimated that 10% of GCs are unnoticed, constituting missed gastric cancer (MGC). To analyse the incidence of MGC in our area, the characteristics of GC and factors related to MGC were evaluated.

137. Machine learning for predicting all-cause mortality of metabolic dysfunction-associated fatty liver disease: a longitudinal study based on NHANES.

作者: Xueni Wang.;Huihui Chen.;Luqiao Wang.;Wenguang Sun.
来源: BMC Gastroenterol. 2025年25卷1期376页
The mortality burden of metabolic dysfunction-associated fatty liver disease (MAFLD) is rising, making it crucial to predict mortality and identify the factors influencing it. While advanced machine learning algorithms are gaining recognition as effective tools for clinical prediction, their ability to predict all-cause mortality of MAFLD individuals remains uncertain. This study aimed to develop different machine learning models to predict all-cause mortality of MAFLD individuals, compare the predictive performance of these models, and identify the risk factors contributing all-cause mortality, which is crucial for management of MAFLD individuals.

138. Artificial Intelligence in Gastroenterology and Hepatology: Potential and Perils.

作者: Dennis L Shung.;Marietta Iacucci.
来源: Gastroenterology. 2025年

139. Impact of medical therapy on liver transplant eligibility in patients with portopulmonary hypertension: a systematic review.

作者: Matthew T Siuba.;Ahmed Abushamma.;Aman Qureshi.;Shelley Ivary.;Adriano R Tonelli.
来源: Minerva Gastroenterol (Torino). 2025年
Portopulmonary hypertension (PoPH) occurs in roughly 5% of patients evaluated for liver transplant and increases perioperative morbidity and mortality. PoPH patients often succumb to complications of the underlying liver disease, therefore liver transplantation can be a lifesaving intervention. Medical treatment of PoPH optimizes patients for transplantation, but the knowledge on the effect of PH specific therapy on transplant eligibility is limited.

140. Clinical characteristics of MASLD/MetALD/MAFLD/NAFLD and the relative risk analysis on metabolic disorders.

作者: Hong-Ye Peng.;Chun-Li Lu.;Mo Zhao.;Xiao-Qiang Huang.;Shu-Xia Huang.;Zi-Wen Zhuo.;Jing Liu.;Yan-Ping Lu.;Wen-Liang Lv.
来源: BMC Gastroenterol. 2025年25卷1期372页
Our objective was to compare the clinical features of Metabolic dysfunction-associated steatotic liver disease (MASLD) /metabolic alcohol-related liver disease (MetALD)/metabolic associated fatty liver disease (MAFLD)/nonalcoholic fatty liver disease (NAFLD) and the relative risk analysis of metabolic disorders.
共有 39712 条符合本次的查询结果, 用时 4.6792631 秒